Novartis is a Swiss multinational pharmaceutical corporation headquartered in Basel. The company was formed in 1996 through the merger of Ciba-Geigy and Sandoz and is one of the world’s largest pharmaceutical companies.
Bristol Myers Squibb will deploy Anthropic’s Claude across global operations, putting the AI platform in the hands of more than 30,000 employees. BMS plans to use it in R&D, clinical development, manufacturing and commercial work.
Novartis reported Phase III PSMAddition data showing Pluvicto plus standard of care cut the risk of PSA progression by 58% in PSMA-positive metastatic hormone-sensitive prostate cancer. Regulatory decisions in the United States, China and Japan are expected in the second half of 2026.
Vanguard and Goldman Sachs forecasts pointed to stronger long-term returns for international stocks than for U.S. equities. The articles highlighted broad international, European and emerging-market ETFs with low expense ratios and large exposure to non-U.S. markets.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
Novartis introduced new long-term social impact and sustainability targets covering access, global health, emissions, waste and water. The plan includes a 2030 access goal and net-zero across the value chain by 2040.
Novartis finalized a seventh new US facility as part of a $23 billion expansion. The new API site in Morrisville, North Carolina, supports end-to-end US manufacturing across multiple therapy platforms.
Olema Pharmaceuticals appointed Prakash Raman, Ph.D., to its board of directors. The company said the oncology deal veteran joins as Olema advances palazestrant and OP-3136 while remaining loss-making.
Novartis received EU approval for Rhapsido (remibrutinib) as the first oral targeted treatment for chronic spontaneous urticaria. Phase 3 data also showed significant efficacy in chronic inducible urticaria, with filings underway for additional indications.
Isomorphic Labs said one AI-designed drug, ISM8969, has FDA clearance for human clinical trials. The company’s initial pipeline focuses on oncology candidates.
WHO has prequalified Coartem Baby, the first malaria treatment developed for newborns and young infants weighing 2 to 5 kilograms. The decision opens access through public procurement and donor-funded programs.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07549646 |
24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07549139 |
Overcoming Racial Disparities in Screening Mammography |
NOT_YET_RECRUITING | NA |
| NCT07543822 |
24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07538401 |
ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07493408 |
Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML |
NOT_YET_RECRUITING | PHASE2 |
| NCT07443137 |
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) |
NOT_YET_RECRUITING | PHASE1 |
| NCT07434180 |
Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary |
NOT_YET_RECRUITING | PHASE2 |
| NCT07431931 |
Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria |
NOT_YET_RECRUITING | NA |
| NCT07415824 |
Multiple Sclerosis Implementation Network (Registry) |
RECRUITING | |
| NCT07382414 |
Electronic Letters to Improve Patient Activation in IHD: The NUDGE-IHD Trial |
NOT_YET_RECRUITING | NA |
